Responsible innovation.
暂无分享,去创建一个
[1] U. Galili,et al. Variations in activity of the human natural anti-Gal antibody in young and elderly populations. , 1995, The journals of gerontology. Series A, Biological sciences and medical sciences.
[2] M. Si,et al. Short-term experience of porcine small intestinal submucosa patches in paediatric cardiovascular surgery. , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[3] M. Pozzi,et al. Preliminary experience in the use of an extracellular matrix to repair congenital heart diseases. , 2011, Interactive cardiovascular and thoracic surgery.
[4] C. Mitcham,et al. Midstream Modulation of Technology: Governance From Within , 2006 .
[5] Stephen F Badylak,et al. Natural anti-galactose alpha1,3 galactose antibodies delay, but do not prevent the acceptance of extracellular matrix xenografts. , 2002, Transplant immunology.
[6] M. Stelly,et al. Histology of CorMatrix bioscaffold 5 years after pericardial closure. , 2013, The Annals of thoracic surgery.
[7] Kimberlee Gauvreau,et al. Preliminary experience with porcine intestinal submucosa (CorMatrix) for valve reconstruction in congenital heart disease: histologic evaluation of explanted valves. , 2014, The Journal of thoracic and cardiovascular surgery.